Targeted Delivery of an Antibody–Mutant Human Endostatin Fusion Protein Results in Enhanced Antitumor Efficacy
暂无分享,去创建一个
J. Merchan | S. Ramakrishnan | J. Rosenblatt | Seung-uon Shin | K. Kovács | Jin Zhang | Yawu Jing | Hyun‐Mi Cho
[1] Y. Guan,et al. Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. , 2007, World journal of gastroenterology.
[2] Na Lu,et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. , 2007, Biochemical and biophysical research communications.
[3] J. Sosman,et al. Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses , 2007, Clinical Cancer Research.
[4] John V Heymach,et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] O. Sürücü,et al. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. , 2005, Cancer research.
[6] G. Giaccone,et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] S. Morrison,et al. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein , 2005, Molecular Cancer Therapeutics.
[8] G. Bubley,et al. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox‐2 inhibition , 2005, International journal of cancer.
[9] S. Ramakrishnan,et al. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth , 2004, International journal of cancer.
[10] E. Van Cutsem,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[11] R. Wolff,et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[13] D. Slamon,et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. , 2004, Journal of the National Cancer Institute.
[14] W. Eiermann,et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. , 2004, Journal of the National Cancer Institute.
[15] R. Schilsky,et al. Cancer and Leukemia Group B 90206 , 2004, Clinical Cancer Research.
[16] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Ramakrishnan,et al. Improved biological activity of a mutant endostatin containing a single amino-acid substitution , 2004, British Journal of Cancer.
[18] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[19] A. Gottlieb,et al. Etanercept as monotherapy in patients with psoriasis. , 2003, The New England journal of medicine.
[20] J. Weinberg. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. , 2003, Clinical therapeutics.
[21] M. Cattaneo,et al. Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities. , 2003, Journal of medicinal chemistry.
[22] E. Winer,et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] V. Sukhatme,et al. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. , 2003, Journal of the National Cancer Institute.
[24] M. Cattaneo,et al. Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. , 2003, Experimental cell research.
[25] Andreas Friedl,et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] W. Pickl,et al. Laminin Modulates Morphogenic Properties of the Collagen XVIII Endostatin Domain* , 2002, The Journal of Biological Chemistry.
[27] A. Feldman,et al. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin , 2002, International journal of cancer.
[28] L. Ellis,et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Donald W Kufe,et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. D'Amato,et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. , 2001, Cancer research.
[31] B. Olsen,et al. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. , 2001, Cancer research.
[32] G. Garcı́a-Cardeña,et al. Oligomerization-Dependent Regulation of Motility and Morphogenesis by the Collagen Xviii Nc1/Endostatin Domain , 2001, The Journal of cell biology.
[33] T. Kuzel,et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. , 2001, Clinical lymphoma.
[34] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[36] S. Morrison,et al. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. , 1998, Journal of immunology.
[37] K. Preissner,et al. Isolation and characterization of the circulating form of human endostatin , 1997, FEBS letters.
[38] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[39] S. Morrison,et al. Functional and pharmacokinetic properties of antibody-avidin fusion proteins. , 1997, Journal of immunology.
[40] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[41] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Morrison,et al. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. , 1992, Journal of immunological methods.
[43] S. Yuan,et al. Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys , 2005, Acta Pharmacologica Sinica.
[44] F. Kabbinavar,et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Barbara L. Smith,et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Rolf Bjerkvig,et al. Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. , 2002, Neuro-oncology.
[47] Anthony Atala,et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy , 2001, Nature Biotechnology.
[48] V. Sukhatme,et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. , 1999, Cancer research.
[49] S L Morrison,et al. Production and properties of chimeric antibody molecules. , 1989, Methods in enzymology.